Clinical Study of BRL-101 in Severe SCD

Sickle Cell Disease Clinical Trial

Official title:

Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of CRISPR/Cas9-edited Autologous CD34 + Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Severe Sickle Cell Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06300723
• Other study ID #: 2024-BRL-101-SCD-01
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 25, 2024
• Est. completion date: June 15, 2026

Study information

• Verified date: March 2024
• Source: Bioray Laboratories
• Contact: Yongrong Lai, phD
• Phone: 0771-5356510
• Email: laiyongrong[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101).

Description:

This clinical trial is a single-arm, single-dose, single center, open-label study without dose escalation. The primary objective is to explore the safety of the study drug in SCD. Myeloablative conditioning and administration for the remaining subjects can only be started after the first subject completes dosing and safety observation and assessment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1
• Est. completion date: June 15, 2026
• Est. primary completion date: March 20, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 35 Years

Eligibility

Inclusion Criteria:

-

Subjects must meet all the following inclusion criteria to be eligible for enrolment into the study:

1. Subject (or their legally authorized representative or guardian) will sign and date an informed consent form (ICF) and, where applicable, an assent form.

2. Subjects 3 to 35 years of age, inclusive, on the date of informed consent.

3. Clinically confirmed severe SCD, genotypes include: ßS/ßS, ßS/ß + or ßS/ß0. Severe SCD is defined as having at least 2 VOC events per year during the 2 years prior to screening and requiring appropriate supportive care, including a pain management program, HU therapy (if indicated).

4. Karnofsky performance status of =80% for subjects =16 years of age. Lansky performance status of =80% for subjects <16 years of age (see Appendix 1 and 2).

5. Eligible for autologous stem cell transplant as per investigator's judgment.

6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other study procedures.

7. Willing to participate in an additional long-term follow-up study after completion of this study (Study 2022-LTF-BRL-101).

8. Subjects of childbearing potential must use effective contraception for at least 6 months after BRL-101 infusion during the study.

Exclusion Criteria:

-

Subjects meeting any of the following criteria are not eligible for enrolment in the study:

1. Known contraindications, intolerance, or hypersensitivity to hematopoietic stem cell mobilizers, busulfan injection, or dimethyl sulfoxide (DMSO) or study drug-related components.

2. Eligible for allogeneic hematopoietic stem cell transplantation and have found HLA-identical donors.

3. Prior allo-HSCT, gene therapy or gene editing therapy.

4. Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator.

5. HbF level >15.0%, irrespective of concomitant treatment with HbF inducing treatments such as HU.

6. Treatment with regular RBC transfusions that, in the opinion of the investigator, cannot be interrupted after engraftment.

7. More than 10 unplanned hospitalizations or emergency department visits related to SCD in the 1 year before screening and the investigator considered this to be a significant chronic pain rather than an acute pain crisis.

8. A history of clinically significant transcranial Doppler (TCD) test abnormalities or test abnormalities in the opinion of the investigator.

9. History of untreated Moyamoya disease or presence of Moyamoya disease at Screening that in the opinion of the investigator puts the subjects at the risk of bleeding.

10. the subject has participated in other clinical studies and used drugs within 3 months before screening.

11. White blood cell count < 3 × 109/L and/or platelet count < 100 × 109/L not due to hypersplenism as judged by the investigator.

12. INR > 1.5×ULN, APTT > 1.5×ULN.

13. Creatinine > 1.5 × ULN or endogenous creatinine clearance < 60 ml/min (calculated according to the Cockcroft-Gault formula, see Appendix 3).

14. ALT or AST> 3×ULN, or direct bilirubin value > 2.5×ULN.

15. Severe iron overload with serum ferritin = 5000 ng/ml, liver iron > 15 mg Fe/g dry weight (or liver MRIT2* < 1.4 ms or > 588 Hz), or heart MRI-T2* < 10 ms.

16. LVEF < 50%.

17. DLco < 50% predicted (corrected haemoglobin or/and alveolar volume) or forced vital capacity (FVC) (measured/predicted) < 60% (For children for whom DLco could not be determined), or abnormal blood gas analysis (for younger children with undetectable ventilatory function only).

18. Hepatitis B virus surface antigen (HBsAg) positive or HBV-DNA positive; hepatitis C virus (HCV) antibody positive; human immunodeficiency virus (HIV) antibody positive; syphilis (TP) -specific antibody positive; Epstein-Barr virus EBV-DNA positive; cytomegalovirus CMV-DNA positive.

19. History of a significant bleeding disorder.

20. History or family history of malignancy or myeloproliferative disorder.

21. Any prior or current cardiovascular system diseases, such as congestive heart failure, arrhythmia, myocardial disease, valvular heart disease or pulmonary hypertension; cirrhosis, liver fibrosis or active hepatitis; central nervous system diseases or mental illness.

22. Presence of immune dysfunction or endocrine disorders, such as insulin-dependent diabetes mellitus, hyperthyroidism, or insufficiency.

23. Pregnant or breastfeeding females.

24. Any condition that, in the opinion of the investigator, would make participation in this clinical study inappropriate.

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• BRL-101
CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.

Locations

Country	Name	City	State
China	First Affiliated Hospital of Guangxi Medical University	Nanning	Guangxi

Sponsors (2)

Lead Sponsor	Collaborator
Bioray Laboratories	First Affiliated Hospital of Guangxi Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of stem cell engrafted subjects	Stem cell engraftment was defined as an absolute peripheral blood neutrophil count of = 0.5 × 109/L for 3 consecutive days following BRL-101 intravenous infusion	Within 42 Days After BRL-101 Infusion
Primary	Time to neutrophil engraftment	Defined as Day 1 of absolute peripheral blood neutrophil count = 0.5 × 109/L for 3 consecutive days	Within 42 Days After BRL-101 Infusion
Primary	Frequency, severity, and relationship to BRL-101 of adverse events over 12 months following BRL-101 infusion	Adverse events assessed according to NCI-CTCAE v5.0 criteria	Up to 12 Months After BRL-101 Infusion